Companies / Melodia Therapeutics
Melodia Therapeutics
Basel, Switzerland
Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.
Melodia Therapeutics, based in Basel, Switzerland, has 1 investor on file, among them FORTY51 Ventures. Its site was last checked 9 Nov 2026: site answers.
Investors
1 investor on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital |
More from FORTY51 Ventures
5 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (100%).
See FORTY51 Ventures' full profile · Who invests alongside it
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Melodia Therapeutics and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when FORTY51 Ventures adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/melodiatx.com/investors
# also
GET /v1/companies/melodiatx.com
GET /v1/companies/melodiatx.com/news